3-环己基吡咯烷-2-酮 | 911721-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3-环己基吡咯烷-2-酮
• 英文名称: 3-cyclohexylpyrrolidin-2-one
• CAS: 911721-88-5
• 化学式: C₁₀H₁₇NO
• 分子量: 167.251
• InChiKey: AJMIHOJVLPTIEL-UHFFFAOYSA-N

物化性质

• 沸点：
  330.2±11.0 °C(Predicted)
• 密度：
  1.036±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

反应信息

• 作为产物：
  描述：

  4,5-二氢-3-苯基-2-呋喃酮 在 5% rhodium-on-charcoal 氨 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 60.0~230.0 ℃ 、413.7 kPa 条件下， 反应 36.0h， 生成 3-环己基吡咯烷-2-酮
  参考文献：
  名称：

  WO2007/127726

  摘要：

  公开号：

文献信息

• 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS
  申请人：CHEN Huanming

  公开号：US20080234334A1

  公开（公告）日：2008-09-25

  This invention is directed to compounds of formula I, where G is —O—, —S—, —C(g 1 )(g 2 )-, or —NH—, and n=1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.

  本发明涉及公式I的化合物，其中G为—O—、—S—、—C(g1)(g2)-或—NH—，n=1、2或3。这些化合物调节钾离子通道。这些化合物可用于治疗和预防受钾离子通道调节影响的疾病和障碍。其中一种情况是癫痫障碍。
• Prophylactic/Therapeutic Agent for Diabetes
  申请人：Cho Nobuo

  公开号：US20090264650A1

  公开（公告）日：2009-10-22

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种11β-羟基类固醇脱氢酶1抑制剂，其包括由式（1）表示的化合物，其中每个符号如描述中所定义的，或其盐或前药。本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，可用作药物剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖症、异常脂质代谢、高血压等的药剂。
• INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Li Renhua

  公开号：US20090099182A1

  公开（公告）日：2009-04-16

  The present invention discloses novel compounds of Formula I: having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

  本发明披露了一种新的I式化合物：具有11β-HSD类型1拮抗剂活性的化合物，以及制备这种化合物的方法。在另一实施例中，该发明还披露了包含I式化合物的制药组合物，以及使用该化合物和组合物治疗糖尿病、高血糖、肥胖症、高血压、高脂血症、代谢综合征和其他与11β-HSD类型1活性有关的疾病的方法。
• Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
  申请人：Eli Lilly and Company

  公开号：US07994176B2

  公开（公告）日：2011-08-09

  The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity. X-17377

  本发明揭示了具有11 Beta-HSD type 1拮抗活性的新型化合物I的公式，以及制备这种化合物的方法。在另一实施例中，本发明揭示了包括化合物I的制药组合物，以及使用这些化合物和组合物治疗糖尿病、高血糖、肥胖症、高血压、高脂血症、代谢综合征和与11 Beta-HSD type 1活性相关的其他疾病的方法。X-17377。
• PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1864971A1

  公开（公告）日：2007-12-12

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种 11β-羟基类固醇脱氢酶 1 抑制剂，由式（1）代表的化合物组成： 其中各符号如说明中所定义，或其盐，或其原药。本发明的11β-羟类固醇脱氢酶1抑制剂具有优异的活性，可作为药物制剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖、脂代谢异常、高血压等疾病的药物。